Global Fondaparinux Market, By Type (Deep Vein Thrombosis, Pulmonary Embolism), Treatment (Medication, Others), Route of Administration (Parenteral, Others), Product Type (Branded and Generics), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Fondaparinux Market Analysis and Size
As per the American Heart Association, in 2019, the occurrence rate of cardiovascular disease between age 60 and 79 years was around 77.2% for men and 78.2% for women. The majority of diseases such as heart infections and orthopedic conditions anticipate a boost to the market in the upcoming years. It has been observed that the generics segment of the fondaparinux market is projected to be dominant because of the availability of generic drugs at a lower cost and their effectiveness.
Data Bridge Market Research analyses a growth rate in the fondaparinux market in the forecast period 2023-2030. The expected CAGR of fondaparinux market is tend to be around 6.7% in the mentioned forecast period. The market was valued at USD 574.94 million in 2022, and it would grow up to USD 965.91 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Fondaparinux Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Deep Vein Thrombosis, Pulmonary Embolism), Treatment (Medication, Others), Route of Administration (Parenteral, Others), Product Type (Branded and Generics), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Bayer AG (Germany), GSK Plc. (U.K.), Boehringer Ingelheim International GmbH (Germany), Sanofi (France), Apotex (Canada), Abbott (U.S.), Aspen Holdings (South Africa), Bristol-Myers Squibb Company (U.S.), Eisai Co., Ltd (Japan), Aurobindo Pharma (India), Mylan N.V. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Fondaparinux is a synthetic anticoagulant used to prevent the formation of blood clots based on the pentasaccharide sequence, which makes up the minimal antithrombin binding region of heparin. It is an indirect inhibitor of factor Xa having the molecular weight same like heparins. Fondaparinux has a longer half-life than heparin and does not interact with platelets.
Global Fondaparinux Market Dynamics
Drivers
- Growing Risk of Elderly Population Having CVD Risk
As per the records of the United Nations, World Population Prospects: The 2019 Revision, by 2050, one in six people in the world is aged above 65 years, up from one in 11 in 2019. Elderly population is more susceptible to chronic illnesses and it requires immediate and effective treatment for better clinical outcomes, the market is projected to be impacted considerably. In 2019, according to the American Heart Association, the occurrence rate of cardiovascular disease between age 60 and 79 years was 77.2% for men and 78.2% for women.
- Growing Healthcare Expenditure
The rising net profit of several key market players and its associated funds and expenditure from various organizations leads to the growth of the market. For instance, in May 2020, Dr. Reddy's Laboratories announced a 4% growth in its consolidated net profit at Rs 1,949.8 crore for the financial year ended March 31, 2020, wherein the global generics accounted to INR 3,640 crore, with an increase by 20% from F.Y. 2019.
Opportunities
- Increasing Demand of Generics Drug Type
As per the study published in the Journal of American Heart Association, 2020, fondaparinux was found to exhibit an augmented efficiency in the reduction of venous thromboembolism, than low molecular weight heparin, during the treatment for perioperative surgical thromboprophylaxis. Furthermore, as per the research study that is published in the American Heart Association Journal, 2018, compared to enoxaparin for the treatment of non-ST-elevation acute coronary syndrome (NSTE-ACS) patients, fondaparinux was found to be comparatively cost-effective in a Canadian hospital setting.
- Increased Condition of Deep Vein Thrombosis (DVT)
Deep Vein Thrombosis (DVT) is the type of condition in which clot formation takes place in deep veins, and its associated severity may lead to pulmonary embolism. As per the research article published in Medscape, 2019, death from DVT-associated massive pulmonary embolism causes as many as 300,000 deaths annually in the U.S. This boosts the market growth.
Restraints/Challenges
- High Cost of Treatment
The increased expenditure that is required for the diverse treatment processes hamper the market growth. Frequent market players make huge investments in manufacturing new and advanced treatment procedures to increase the recovery process, and in return, the cost is increased.
This fondaparinux market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the fondaparinux market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Fondaparinux Market
COVID-19 has dramatically impacted the fondaparinux market is not exception. Though, the use of heparin is witnessed to show a decreased mortality rate in COVID-19 patients. As per the Journal of Cardiovascular Pharmacology, 2020, the initial results from the study focused the safe and effective use of fondaparinux to decrease the rate of mortality among COVID-19 patients. It is also recommended that fondaparinux be used to some extent because of its long half-life and lack of an antidote. Therefore, different opinions given regarding the usage of fondaparinux in COVID-19 patients, the studied market is projected to be impacted during the COVID-19 pandemic.
Recent Development:
- In 2021, Bayer introduced Vynyty Citrus during the International Symposium on Horticulture in Europe named SHE2021. It is its latest biological and pheromone-based crop protection product for controlling citrus farm pests.
Global Fondaparinux Market Scope
The fondaparinux market is segmented on the basis of types, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Deep Vein Thrombosis
- Pulmonary Embolism
Treatment
- Medication
- Others
Route of Administration
- Parenteral
- Others
Product type
- Branded
- Generics
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Fondaparinux Market Regional Analysis/Insights
The fondaparinux market is analyzed and market size insights and trends are provided by types, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the fondaparinux market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market due to the focus of global players on novel technology or formulation of existing drugs.
Asia-Pacific is considered to grow over the coming years due to high prevalence of drug addiction and number of generic drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Fondaparinux Market Share Analysis
The fondaparinux market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to fondaparinux market
Key players operating in the fondaparinux market include:
- Pfizer Inc.(U.S.)
- Bayer AG (Germany)
- GSK Plc. (U.K.)
- Boehringer Ingelheim International GmbH (Germany)
- Sanofi (France)
- Apotex (Canada)
- Abbott (U.S.)
- Aspen Holdings (South Africa)
- Bristol-Myers Squibb Company (U.S.)
- Eisai Co., Ltd (Japan)
- Aurobindo Pharma (India)
- Mylan N.V. (U.S.)
SKU-